TrialThe New England journal of medicine2013
Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma.
Omid Hamid et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
1,775 papers cite itlatest 60 shown
this paperpooled ittrialcites it